Azaya公司首席执行官Mike Dwyer近期接受SAN ANTONIO商业期刊采访时指出,与北海康成共同开发ATI-1123是Azaya在美国以外开展新产品研发战略合作伙伴的不二选择


CANbridge, Azaya Ink Deal to Develop ATI-1123 for NSCLC
By Shannon Ellis, Staff Writer

SHANGHAI – Beijing newcomer CANbridge Life Sciences Ltd. has partnered with emerging nanotech specialist Azaya Therapeutics Inc., of San Antonio, to develop non-small-cell lung cancer (NSCLC) treatment ATI-1123 in China and North Asia. ATI-1123 is a liposomal formulation of docetaxel that has successfully completed U.S. FDA-approved Phase I trials for multiple solid tumor cancers.

Lung cancer is the most prevalent solid tumor cancer in China. The in-licensing deal for ATI-1123 marks CANbridge’s unoffi cial launch. Small in size, the 10-person team comes with a strong pedigree. Founder and CEO James Xue was the founding general manager of Genzyme China and is an early returnee who came back to China with an MBA and PhD from the U.S. Crystal Xu heads up clinical development and is the former director of medical and regulatory affairs at Genzyme.

For more, please read BioWorld Today VOLUME 24 , NO. 183, Page 7.